

2012

Advancing Our Understanding of the Inheritance and Transmission of Pectus Excavatum

Lisa Horth
Old Dominion University

Michael W. Stacey
Old Dominion University, mstacey@odu.edu


Virginia K. Proud

Kara Segna

Chelsea Rutherford
Old Dominion University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs

 Part of the [Genetic Processes Commons](#), [Genetics and Genomics Commons](#), and the [Pediatrics Commons](#)

Repository Citation

Horth, Lisa; Stacey, Michael W.; Proud, Virginia K.; Segna, Kara; Rutherford, Chelsea; Nuss, Donald; and Kelly, Robert E., "Advancing Our Understanding of the Inheritance and Transmission of Pectus Excavatum" (2012). *Bioelectrics Publications*. 64.
https://digitalcommons.odu.edu/bioelectrics_pubs/64

This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.

Authors

Lisa Horth, Michael W. Stacey, Virginia K. Proud, Kara Segna, Chelsea Rutherford, Donald Nuss, and Robert E. Kelly

1 Original Article

2

3 Advancing our understanding of the inheritance and transmission of pectus excavatum

4

5 Running title: Inheritance of pectus excavatum

6

7 Lisa Horth, MSc, PhD^{a*}, Michael W. Stacey, PhD^{b,c}, Virginia K. Proud, MD^d, Kara Segna, BS^c,
8 Chelsea Rutherford, BS^a, Donald Nuss, MD^e, and Robert E. Kelly, MD^e

9

10 ^a*Dept of Biological Science, Old Dominion University, Norfolk VA USA 23529*

11

12 ^b*Center for Bioelectrics, Old Dominion University, Norfolk VA USA 23529*

13

14 ^c*Center for Pediatric Research, Eastern Virginia Medical School, Norfolk VA 23510*

15

16 ^d*Department of Medical Genetics and Metabolism, Children's Hospital of The King's Daughters
17 and Department of Pediatrics, Eastern Virginia Medical School, Norfolk VA USA 23507*

18

19 ^e*Department of Surgery, Eastern Virginia Medical School and Pediatric Surgery Division,
20 Children's Hospital of The King's Daughters, Norfolk VA USA 23507*

21

22

23 *Correspondence: Lisa Horth, PhD

24

25 110 MGB, Department of Biology

26

27 Old Dominion University

28

29 Norfolk, VA, 23529

30

31 Tel: 001 (757) 683-6508; Fax 001 (757) 683-5283

32

33 Email address: lhorth@odu.edu

34

34 **Abstract.** Pectus excavatum is the most common congenital chest wall abnormality expressed in
35 children, yet its inheritance is poorly understood. Here we present the first comprehensive
36 assessment of the inheritance of this disorder. After evaluating 48 pedigrees and 56 clinical traits
37 of probands and family members, we find strong evidence of autosomal recessive, genetic
38 control for this disorder. Additionally there is likely more than one disease-associated allele as
39 well as a relatively large number of disease allele carriers in the human population. Some clinical
40 traits appear important and may serve as reliable indicators for predicting the likelihood of PE in
41 children before severe symptoms present. Quantifying sex-ratio bias in probands demonstrates a
42 highly significant male bias associated with PE. When combined with pedigree data, sex-bias is
43 indicative of sex-linked, sex-limited, and/or epigenetic control such as X-inactivation, reiterating
44 a point made with pedigrees alone, which is that more than one mutation is likely responsible for
45 this disorder.

46

47 Key words: disease, heritable, genetic, association study

48

48 **1. Introduction**

49

50 Pectus excavatum (PE) is the most common congenital chest wall malformation, occurring in
51 ~1/400 infants and children, primarily male (1-3). The PE phenotype is expressed as an anterior
52 chest cavity depression that results from rotation, displacement, and depression of the sternum.
53 PE has previously been qualitatively described to some degree, yet despite a very high rate of
54 occurrence, its heritability has been only cursorily evaluated (2). PE probands present with
55 various clinical features also found with Marfan syndrome, another connective tissue disorder.
56 Additionally, over one-quarter (28%) of Marfan syndrome probands express PE (4-5).

57 Multiple, independent mutations in the *FBNI* (15q21) gene are associated with a range of
58 clinical manifestations of Marfan syndrome (5-6). While no single gene, or large-scale genomic
59 studies have been conducted on the inheritance of PE, several genes, including *FBN2* (5q23-31),
60 *COL2A1* (12q13), *ACAN* (15q26.1), *TGF β* (19q13) and receptors (*TGF β r1* (9q22), *TGF β r2*
61 (3q22), and *TGF β r3* (1p33)) are associated with connective tissue disorders and thus could be
62 considered candidate loci for PE. Very recent work evaluating one family via genome-wide
63 linkage analysis suggested partial genetic control of PE on chromosome 18, however no
64 causative genes were identified (7).

65 Here we assess 48 pedigrees and a broad array of clinical traits (n=56) in more than 2,000
66 individuals over 100 of whom have PE. Visual inspection of probands provides evidence for
67 multiple, conspicuous clinical features (*e.g.* tallness, thinness, light-eyes) that commonly
68 manifest with PE. We have quantified data related to several clinical traits and added this to
69 conventional pedigrees that we have constructed. We find that this trait-related information
70 contributes to predicting the likelihood that an individual inherits PE. We present results from
71 our analysis of a comprehensive data set to provide evidence that PE is an autosomal, recessive

72 trait or results from polygenic inheritance. We suggest chromosomal regions relevant for future
73 genome wide association studies for PE-alleles. We show evidence for the Carter effect (8), a
74 polygenic inheritance pattern with a susceptibility threshold that differs for the sexes and that
75 results in a predictable sex-related transmission pattern (9, 10). We demonstrate evidence of
76 strong male bias in probands. Finally, we estimate the frequency of PE alleles and of carriers in
77 the human population. Results from our study may prove useful for determining the likelihood of
78 development of this disorder in unborn children and for locating genes controlling PE.

79 **2. Materials and methods**

80 **Pedigree construction, inheritance, and sex-ratio**

81 We have constructed pedigrees (Figure 1) based upon detailed information obtained during
82 medical examination of probands and from self-reported data of immediate family members of
83 individuals with PE severe enough to warrant surgical correction. Eastern Virginia Medical
84 School IRB approved questionnaires were used to obtain these data, which address filial history
85 of PE and a broad array of clinical features (discussed below). The population assessed is of
86 national origin, though is comprised primarily of Caucasian males from the mid-Atlantic. They
87 are a subset of the national registry of individuals at the Children's Hospital of The King's
88 Daughters seeking surgical intervention. Forty-eight family pedigrees are constructed and each is
89 comprised of at least four, and sometimes five, generations (though little information was
90 typically known for the eldest generation).

91 The likelihood that spontaneous mutation, or a particular inheritance pattern (here
92 considered: X-linkage, Y-linkage, autosomal dominant, autosomal recessive or semi-dominant
93 control, sex-linkage coupled with an autosomal modifier, or polygenic inheritance), best explains

94 each pedigree is evaluated. This conventional analysis excludes impossible scenarios but does
95 not yield a single, inheritance pattern for each family.

96 Therefore we supplemented the pedigrees with data regarding genes that control PE-
97 associated clinical traits onto our pedigrees and re-evaluated for most probable mode of
98 inheritance. Persons with autosomal traits that might be linked to PE genes demonstrate potential
99 heritability information not available in the first analysis (*e.g.* what previously appeared, perhaps
100 erroneously, to be a spontaneous mutation may now present with parent carrier phenotypes) and
101 a polygenic mode of inheritance is plausible. Hence, the Carter effect is examined by assessing
102 the relative rate of transmission of PE from females with PE (compared to males) to progeny
103 with the expectation that women transmit to their progeny at a higher rate if a polygenic
104 threshold model fits these data. Six additional families are added for this analysis only, to
105 increase the sample size of the smallest cells in the contingency tables. The two by two
106 contingency table is presented for all children (with and without PE) that have one parent that
107 expresses PE (Table 2). Data are then presented for this same group of children, partitioned by
108 sex. A binary logistic regression was performed to assess the association between mothers or
109 fathers that had PE and their progeny that did (versus did not) express the disorder. An odds ratio
110 is presented with 95% confidence intervals and the p value for the associated Chi-square test.

111 Another table (Table 3) is presented to evaluate the association between the number of
112 siblings expressing PE (versus not) when the sex of the affected individual is male versus female.
113 The same analyses are presented. Analyses were conducted using SPSS 12.0 (IBM, NY, USA).

114 Finally, we evaluated sex ratio bias in individuals with PE. Pearson chi-square analysis was
115 conducted on the male: female ratio observed in the pedigrees (11). Several cases of pectus
116 carinatum (PC, a similar disorder to PE except here the chest wall is everted) were reported in

117 families with PE. Since the inheritance of PC is also not understood, we analyzed the sex ratio
118 for PC with an exact binomial test for goodness of fit for deviation from 1:1 (12). Miscarriage
119 data were also evaluated to determine whether a lethal allele might drive the sex ratio bias
120 observed in PE (*e.g.* X_{PE} causes PE in males and $X_{PE}X_{PE}$ is lethal in females).

121 **Quantification of clinical traits**

122 Fifty-eight clinical traits were assessed for 56 families to identify the traits most frequently
123 associated with PE. Traits generally fell into broad categories including cardiac function,
124 musculo-skeletal system function, and behavior. Some specific traits included mitral valve
125 prolapse, height, finger length, skin tone, myopia, ADHD and depression. Table 1 ranks the 10
126 most common traits for individuals with PE and compares this to the 10 most common traits for
127 family members without PE.

128 Using NCBI human genome data (13) to identify chromosomal locations of genes controlling
129 the common traits assayed, we created a trait-related genomic map (Figure 2), allowing us to
130 collect data on specific chromosomes that might be more likely to carry PE-related genes if
131 linkage exists between these clinical trait genes and PE genes.

132 ‘Tall’ and ‘thin’ are clinical traits commonly associated with PE but only qualitative data was
133 included in our database regarding these. Therefore, we obtained independent quantitative data
134 on these traits in individuals with PE from the thread found at the website dedicated to PE where
135 individuals communicate regarding their condition (14). This thread included 179 self-reported
136 responses to the Oct 6, 2004 query ‘How tall/thin are you PE people?’ We performed chi-square
137 tests to compare average height and weight between individuals with PE and the U.S. adult
138 population.

139 **Estimating the frequency of heterozygotes**

140 If PE arises from autosomal recessive mutations like many other human diseases then the
141 expected frequency of heterozygous carriers can be calculated, assuming Hardy-Weinberg
142 equilibrium. We perform this calculation using the phenotypic expression range found in the
143 literature (1/400-1/1,000 individuals) for PE. We address single- versus multiple-gene
144 involvement in PE and the effect on this calculation.

145 **3. Results**

146 **Pedigree construction, PE-inheritance, and sex-ratio**

147 A total of 2,147 individuals were evaluated from 56 families, wherein 116 individuals
148 present with PE. Cumulatively, inheritance patterns across families reveal the likelihood that
149 more than one PE-associated allele, and possibly an epigenetic effect are important in the
150 heritability of this disorder.

151 As predicted, the conventional method of pedigree analysis is not an especially powerful
152 technique with these data because of the small amount of information available on the pedigrees
153 (e.g. one or a few individuals with PE). Thus, multiple inheritance patterns are possible
154 explanations for disease for most families. When we test whether spontaneous mutation fits as an
155 explanation for PE in each family, we find that it cannot be excluded as a possibility for 17
156 families (and it is a poor fit for 26 families). For five additional cases where PC is also present in
157 the family, spontaneous mutation would explain PE only if PC is genetically unrelated.

158 When we test each pedigree for autosomal control, we find that this could explain the
159 inheritance of PE in all families. However a standard null model for autosomal disorders is that
160 about one-half of cases will be male and one-half female. Our data prove inconsistent with the
161 50:50 sex ratio given the large male-bias observed with PE. Autosomal recessive transmission
162 here also requires multiple marriages to heterozygous individuals in many families, or an

163 epigenetic effect, or sex-limited expression. This fact spurred our Hardy-Weinberg calculation so
164 that we could evaluate the expected PE carrier rate.

165 Alternatively, sex-linked expression combined with an autosomal modifier describes the
166 pedigrees fairly well: X-linkage (or sex limited expression) plus a dominant or recessive
167 autosomal modifier can explain most cases of PE. The limitation of this analysis is that X-
168 linkage plus a modifier is not always a conservative explanation. X-linkage alone is supported
169 for 19 pedigrees and refuted for 19. For five additional cases, X-linkage is very unlikely. For the
170 remaining five cases X-linkage would be contingent upon the relationship between the
171 inheritance of PC and PE.

172 Finally, when we assess Y-linkage across pedigrees, Y linkage (or sex limited expression)
173 plus a dominant or recessive modifier could not be excluded as explaining the inheritance of PE.
174 However, in no case would Y-linkage alone be supported.

175 A more powerful analysis than the above is revealed when incorporating the relevant clinical
176 traits (Table 1) on the pedigrees atop the data regarding PE, since heterozygous individuals will
177 express all linked dominant or semi-dominant (or homozygous recessive) clinical traits, which
178 proves useful for identification of putative PE allele carriers. With this analysis, only two cases
179 of PE are predicted to result from spontaneous mutation, which is more consistent with the very
180 low *de novo* mutation rate for humans ($\sim 10^{-5}$ - 10^{-6}) (15) than the result from the first analysis.
181 The phenotypic expression of PE across generations, though skipping generations in many
182 pedigrees, reinforces the concept that carriers are likely to be important in the inheritance of this
183 disorder. In fact, the inheritance pattern on nearly all pedigrees suggests that linkage with
184 specific regions of chromosome 5 (or, plus 15 and/or 17) is worthy of future genome wide
185 analysis. Here, 19 pedigrees are best fit by a simple autosomal inheritance pattern (13 recessive

186 and six either dominant or recessive). In ~84% of them (16 out of 19 pedigrees), chromosome 5
187 associated-traits appear prominently in family members for whom they might be expected if
188 these traits are linked to PE genes. In three of the autosomal recessive cases, chromosome 15
189 appears similarly.

190 Twenty pedigrees appear best explained by a polygenic effect, where again clinical traits
191 from one or two chromosomes (namely 5 or 15, and/or 17) are inherited in a manner that is
192 consistent with transmission of PE through the family and thus linkage to PE genes warrants
193 future genome wide studies focusing on these chromosomes: chromosomes 5 and 17 appear
194 relevant for five pedigrees, 5 and 15 for six pedigrees, and 5 or 15 and 17 for six more pedigrees.
195 A role for chromosomes 15 and 17 appears relevant for three pedigrees, for chromosome 5 and 1
196 or X important for two pedigrees, and for chromosome 15 and either 7 or X for two more
197 pedigrees. A role for chromosome 7 appears for three pedigrees and one of these looks to have a
198 spontaneous mutation. A final pedigree also appears to present with a spontaneous mutation and
199 no chromosomal traits appear important.

200 Thus, a role for chromosome 5 appears in over half (62.5%, or 30/48) and perhaps as many
201 as 75% (36/48) of the pedigrees. Chromosome 15 appears important for between one-third (29%,
202 14/48) and ~42% (20/48) of the pedigrees. Chromosome 17 appears important in nearly one-fifth
203 (18.75%, 9/48) and up to 31% (15/48) of the pedigrees.

204 Results from the test for a polygenic mode of inheritance with a threshold that differs by sex
205 are shown in Table 2. The rate of transmission from affected mothers (with PE) to children is
206 64% (16/24) and affected fathers to children is 33% (20/59). The Chi-square P value is 0.008
207 and the risk of transmission from mothers over fathers is 3.900, though the confidence interval
208 surrounding the odds ratio is 1.427-10.659. Partitioning this data by the child's sex shows that

209 mothers transmit to their female children in 70% of the cases (7/10) whereas fathers transmit to
210 female children in 17.39% of the cases (4/23). Mothers transmit to sons in 64.28% (9/14) of the
211 cases whereas fathers transmit to sons in 44.46% of the cases (16/36). Odds ratios in both cases
212 suggest that the risk of transmission is higher when the affected parent is female (Table 2).

213 Table 3 demonstrates the rate of PE in affected mother's siblings versus affected father's
214 siblings, which addresses the relative genetic load in affected females versus males. Mothers
215 have 33.33% affected siblings (9/27) whereas fathers have 7.2% (7/96). The odds ratio (6.357) is
216 skewed toward a higher likelihood of the disorder in siblings of affected females.

217 The strong deviation from the 1:1 sex ratio suggests that sex-chromosomes, sex-limited
218 expression, sex-related lethal alleles, or sex-related epigenetic control must be involved in some
219 cases of PE. No useful traits were available to assess on the Y chromosome and X-chromosome
220 traits were considered important in at least three pedigrees.

221 In cases where PC is also found in a family, the analysis is challenging, since the literature
222 does not indicate a specific, known genetic association between these two disorders. Despite this,
223 25% (12/48) of families with PE also demonstrate PC in our pedigrees (two families have
224 multiple cases of PC).

225 Evaluating sex ratio across all PE cases, we observe a strong male bias of nearly 4:1, where
226 the exact ratio is 92:24, which reduces to 3.833:1 and deviates strongly from 1:1 ($\chi^2_{0.05, [1]} =$
227 39.863, $p < 0.0001$), or the conventional expectation for autosomal control whether inheritance is
228 controlled by one gene or is polygenic. A more extreme, 8-fold male bias is observed in cases
229 where the proband is an only child. Here, the exact sex ratio is 17:2, which reduces to 8.5:1 and
230 deviates from 1:1 ($\chi^2_{0.05, [1]} = 11.842$, $p < 0.00006$), indicating that 89% of these probands are
231 male. Thirty families present with an only-child that has PE. For these, a 9-fold male bias occurs

232 and the exact sex ratio is 27 males: 3 females, which reduces to 9:1 and deviates from 1:1, $X^2_{0.05, [1]}= 19.2$, $p<0.0001$). In contrast, in families with sibships where at least one sibling has PE, there
233 is a 3-fold male bias and the exact sex ratio is 50:14, which reduces to 3.57:1 and deviates from
234 1:1 ($X^2_{0.05, [1]}= 20.250$, $p<0.0001$). Similarly, the respondents to the online database questions
235 who indicate their sex (131 individuals) also demonstrate a 3-fold male bias, where the exact sex
236 ratio is 101:30, which deviates from 1:1 ($X^2_{0.05, [1]}= 38.481$, $p<0.0001$).

238 Since extreme male bias is suggestive of lethal $X_{PE}X_{PE}$, the sex ratio for the number of living
239 offspring in a sibship where miscarriage was reported for the mother was evaluated and
240 determined to be ~1:1 (12:13). This does not suggest a disproportionate number of reported
241 miscarriages that were female. Only two sibships were comprised of both PE and miscarriage,
242 and in each there was one live male child with PE. One of these mothers reported one
243 miscarriage and the other mother reported five. Under 1:1 sex ratio, this would suggest that four
244 females and two males were miscarried.

245 A second possibility explaining male bias involves the masking of a recessive X_{PE} by a wild-
246 type X in females. This would result in male biased disease expression (X_{PE} is not masked by Y),
247 as would biased X-inactivation in females, but no expectation of a sex ratio bias in living
248 children was found in sibships with miscarriage. For the recessive X there is a predicted
249 inheritance pattern (heterozygous-mother to expressing son), which is sometimes, but not
250 always, evidenced in our pedigrees. Our pedigrees also include 14 cases of PC (79% in males; 11
251 male: 3 female), which demonstrate a reduced sex ratio of 3.66:1. This is similar to the bias
252 observed for PE.

253 **Quantification of clinical traits**

254 The average number of clinical traits that individuals with PE have is 5.73 ± 3.48 . For family
255 members without the disorder the average is 0.14 ± 0.085 . After excluding individuals with zero
256 traits, the non-PE family members' mean is still lower, at 2.80 ± 0.87 , than for those with PE.

257 The 10 most common clinical traits identified in individuals with PE and their families in this
258 study are reported in Table 1. Ranked from 1-10 for individuals with PE these are: thinness (47%
259 of individuals with PE), braces (41%), myopia (40%), tallness (33%), light eyes (29%), long
260 fingers (25%), creativity (25%), crowded teeth (25%), fair skin (22%), and asthma (20%). The
261 ranking of these traits in family members without the disorder changes and the frequency of the
262 top 10 PE-related traits is always substantially less for family members than for individuals with
263 PE.

264 The chromosomal locations for genes that are known to be associated with the traits are
265 pictured in Figure 2. Some of these are: light eyes (5p13.2, 9p23, 15q11.2, 15q13.1), fair skin
266 (5p13.2, 15q21.1 and 16q24.3), asthma (1q32.1, 5q31-33, 7p14.3, 17q12-21.1 and 20p13) and
267 myopia (1p36, 2q37.1, 3q26, 4q22-q27, 4q12, 5p15.33-p15.2, 7q36, 7p15, 8p23, 11p13, 12q21-
268 q23, 17q21-q22, Xq28, Xq23-q25).

269 Figure 3 lists the 10 most common PE-related traits and identifies which members of the
270 immediate family (mother, father, proband) have each trait. Traits shared between the proband
271 and both parents arise 21 times (yellow cells), between the proband and the mother, 29 times
272 (pink cells), and between the proband and the father, 44 times (light blue cells). This figure also
273 displays the traits that are found only in the proband, which arise 89 times (gray cells), only in
274 the mother, which arise 33 times (dark red cells), only in the father, which arise 39 times (black
275 cells), and between the mother and father, which arise 9 times (green cells). The proband has

276 over twice as many traits as either of his parents (2.69 times more than his mother and 2.28 times
277 more than his father).

278 Regarding height, boys and girls with PE are taller and thinner than the average male and
279 female in the U.S. The average height of adult men (20+ yrs) in the U.S. is 5'9.4" and the
280 average weight is 194.7 lb. (16). Analysis of the PE web site height/weight data indicates that
281 males with this disorder are taller than this, despite being younger: 47 of the 54 male individuals
282 whose data we could analyze (complete information supplied) exceeded 5' 9" and seven were
283 shorter. An appropriate null expectation for height (a normally distributed trait) is that about half
284 of the population (or here the PE subpopulation) will be taller than average (and for PE this
285 would be 27 males), and half will be shorter. Our data deviate substantially from this expectation
286 since 47 of 54 men with PE are taller than average than average ($X^2_{[0.05],1} = 29.629$, $p < 0.0001$).
287 Further, of the 7 males shorter than 5'9", three are less than 18 yrs and four are less than 20 yrs
288 old. In addition, of the 47 males above 5'9", nine are not yet 18 yrs old and are expected to
289 continue to grow. The average age for males evaluated from the web site data was 22.63 yrs.
290 Individuals < 20 yrs were included in the comparison because we had complete data on them
291 (making inclusion possible, which seemed reasonable since this is a conservative action given
292 that they can only grow taller with increasing age). Removing the heights of the boys under 20
293 yrs from the analysis, the result remains highly significant. Similarly, of the 34 men \geq 20 yrs for
294 which we could calculate weight, their average weight was 174.14 lbs. This is ~20 lbs less than
295 the average reported for U.S. men (16).

296 The average height of adult women in the United States is 5'3.8" and average weight 164.4
297 lbs. (16). Females with this disorder are also taller and thinner than the average woman ($X^2_{[0.05],1}$
298 = 9.9 and the $0.001 < p < 0.01$). Of the females' query responses we were able to analyze, five

299 females were < 5'4" and 20 were taller. The average age for the women evaluated from the web
300 site data was 26.1 yrs. Of the five women < 5'4", one was under 18 yrs and potentially still
301 growing. Of the 20 over 5'4", five were ≤ 18 yrs and 2 were ≤ 20 yrs. Similarly, of the 14 women
302 ≥ 20 yrs for which we could calculate weight, the average weight was 119.07 lbs which is ~ 45
303 lbs less than the average reported for U.S. women (16).

304 **Estimating the frequency of heterozygotes**

305 Our pedigree assessment indicates that autosomes are likely involved in this disorder but we
306 find that a relatively large number of marriages between heterozygous individuals must occur if
307 this is true. If PE is a result of a homozygous recessive genotype, then individuals that are
308 heterozygous for alleles causing PE are predicted to be relatively common. If the disease
309 phenotype is represented by the autosomal recessive genotype, ' rr ', then the frequency ' r ' in the
310 population is 0.0025 (from the reported 1 in 400 have the disorder). In Hardy Weinberg, $p^2 =$
311 0.0025, so $p = 0.05$, $q = 0.95$ and the frequency of heterozygotes ($2pq$) equals 0.095, implying
312 that 9.5 in 100 individuals will carry ' r '. This number could increase if PE is additive and
313 polygenic. If two independent mutations cause PE, then 19/100 carriers would be expected and if
314 three independent mutations cause PE then 28.5/100 carriers would be expected.

315 Similarly, if the frequency of ' rr ' = 0.001 (from the reported 1/1,000) then $q = 0.969$ and $2pq$
316 = 0.060. Thus, between 6/100 and 9.5/100 individuals would be carriers of an autosomal
317 recessive allele if one recessive mutation causes PE, and as many as 29 in 100 individuals if say,
318 three independent mutations cause PE. Thus, a large number of heterozygotes would exist in the
319 human population.

320 Many cases of PE fit the autosomal, recessive inheritance pattern well and those that do not
321 generally appear to be sex-linked and under autosomal modifier control. The above calculation
322 would also apply for an autosomal modifier.

323 **4. Discussion**

324 Little is known regarding the genetics and inheritance pattern of pectus excavatum. This
325 work advances our knowledge on many fronts. Spontaneous mutations causing human disease
326 occur on the order of $\sim 10^{-5}$ to 10^{-6} , yet as many as 1 in 400 people express PE, indicating that the
327 majority of cases must not result simply from *de novo* mutations. Knowledge regarding clinical
328 traits commonly associated with PE (like thinness, myopia, crooked teeth and tallness) may be
329 useful during genetic counseling for predicting the probability of transmission of PE alleles. The
330 Carter effect addresses the likelihood of the lesser-affected sex carrying a higher genetic load and
331 expressing a disorder less frequently (than the opposite sex) while being more likely to transmit
332 to progeny and to also have siblings that are affected. Data from our assessment of the Carter
333 effect may also be useful in genetic counseling since it points to a higher probability of mother's
334 with PE (versus father's with PE) transmitting the disorder to offspring, as well as these
335 women's siblings having a higher likelihood of being affected with PE. However, caution must
336 be exercised in drawing full conclusions here since the confidence intervals surrounding these
337 odds ratios tend to be large with our present sample sizes.

338 Since the average height and weight of individuals with PE deviates from the norm and
339 demonstrates the unconventional pattern of a negative association (e.g. tall and thin), the
340 predictive power of this trait combination is enhanced.

341 The relatively high frequency of PE in the human population makes it plausible that a
342 substantial number of heterozygous individuals are involved transmission. The presence of

343 clinical traits in a disproportionate number of probands' parents and siblings may reflect an
344 abundance of heterozygous carriers, predicted here to be at least 38-60 fold more common than
345 diseased individuals. This indicates that marriages to heterozygous carriers could occur
346 frequently.

347 The sex-ratio associated with PE deviates substantially from the conventional expectation for
348 pure autosomal control. This is indicative of sex-linked or sex-limited (epigenetic) expression.
349 Male bias may result if more than one independent mutation causes PE and at least one of these
350 is sex-linked, or if females must have a higher number of specific alleles to express PE because
351 of a sex-related susceptibility difference. Or it may result if gene interactions or sex-related gene
352 silencing occur. Thus, the role for genes like *SOX5* (12p12.1) and *SOX9* (17q24.3-q25.1) that
353 interact during chondrogenesis, activate transcription of *COL2A1* (12q13.11), are associated with
354 sex determination and related to disease (17), should be further explored.

355 Alternatively the biased sex-ratio (which demonstrates even greater bias for sibships with an
356 only child with PE) could result from lethal $X_{PE}X_{PE}$. The sex ratio produced by the mothers that
357 reported miscarriages did not suggest a female-bias in miscarried individuals. However, the
358 sibships comprised of individuals with PE and miscarriages could, except our sample is too small
359 to evaluate objectively so further study is warranted. Another possibility involves the masking
360 of a recessive X_{PE} by a wild-type X, which would result in male biased PE expression (X_{PE} is not
361 masked by Y), as would biased X-inactivation in females. Here, there is no expectation of a sex
362 ratio bias in living children found in sibships with miscarriage, but for the recessive X there is a
363 predicted inheritance pattern (heterozygous-mother to PE-expressing son), which is sometimes,
364 but not always, evidenced in our pedigrees. Noteworthy is that in sibships of more than one child
365 and inclusive of a proband, sex ratio is less biased, potentially indicative of multifactorial

366 inheritance or more than one inheritance pattern and/or epigenetic effects for PE. Biased sex
367 expression, such as we see, is expected when there is a sex-dependent threshold for a trait, as
368 holds for the Carter effect.

369 Other human diseases, such as Prader-Walli syndrome, demonstrate *de novo* deletions on
370 chromosome 15 (at 15q11-13) exclusively of paternal origin, and in a few cases maternal
371 heterodisomy (where two different copies of chromosome 15 are inherited maternally) (18) is
372 indicative of epigenetic control. Unlike most human diseases, some (including neurofibromatosis
373 and Duchenne muscular dystrophy) are associated with a high frequency of *de novo* germ-line
374 mutations (19) which result from older sires (in many taxa, especially mammals) that express a
375 higher germ-line mutation rate (spermatogenic cells from old mice have higher mutation rates
376 than young- or middle-aged mice (19). While we cannot definitively state whether our probands
377 have novel mutations, we are in the process of evaluating whether sire age plays a role in PE
378 (85% of probands' sire are over 30 years old), as it does in Marfan syndrome (17) (which affects
379 ~0.0001-0.0005 of the population) (21-23).

380 There is definitive overlap in traits associated with PE and Marfan syndrome (9) including
381 myopia, dental crowding, scoliosis, and long-fingers (23-25). PE and PC are also identified in
382 about half of the individuals with Marfan syndrome, potentially suggestive of similar causation
383 (24-27) and given the abundance of clinical traits involved, leading us to recommend that PE
384 also be referred to as a syndrome.

385 However, Marfan syndrome demonstrates a 1:1 sex ratio (24) indicative of pure autosomal
386 control, unlike the Pectus disorders. The *FBNI* gene (15q21.1) has been implicated as the
387 predominant cause of Marfan syndrome (28-29) with additional mutations found in *TGFβR2*
388 (e.g. 3p24.1) (30). While chromosome 15 appears important in our analysis for PE, *TGFβR1* and

389 *TGFβR2* are typically associated with Marfan syndrome II, which is less similar to PE than
390 Marfan syndrome.

391 Our current knowledge suggests the potential for greater than one mutation to be associated
392 with PE and the likelihood of sex-biased, polygenic control. Our data points to a clear need for
393 genome-wide analysis of control of this disorder and follow through on establishing the
394 importance of the links identified in this paper in a quantitative analysis. Regions of
395 chromosomes 5, 15, and 17 are relevant for linkage mapping and candidate gene searches since
396 relevant PE-associated clinical traits are controlled by genes on these chromosomes. Genes
397 affecting cartilage are also found on these chromosomes and mutations in some of these genes
398 control other syndromes demonstrating symptoms similar to PE. Aggrecan (*ACAN*, 15q26.1, a
399 major proteoglycan of cartilage (31) accounts for 35% dry weight of cartilage (32) and two
400 fibrillin genes (e.g. *FBNI*, 15q15-21.3 and *FBN2*, 5q23-31) affect connective tissue, causing
401 Marfan and Marfan-like syndrome (33). While this work advances our knowledge regarding PE
402 substantially, candidate gene searches for PE-related mutations are a necessary next step to
403 identifying the causative agent of PE. Equally important are microarrays to look for differences
404 in gene expression between individuals with PE, without PE, and those predicted to be
405 heterozygous for this disorder.

406

406 **Acknowledgement:** Thanks to two anonymous reviewers for very constructive comments. This
407 research was supported by a grant from the Norfolk Foundation to M. Stacey & L. Horth.

408

409 **References**

- 410 1. Chung CS, Myriantopoulos NC. Factors affecting risks of congenital malformations. I.
411 Analysis of epidemiologic factors in congenital malformations. Report from the
412 Collaborative Perinatal Project. *Birth Defects Orig Artic Ser* 1975; 11:1–22.
- 413 2. Creswick HA, Stacey MW, Kelly RE, et al. Family study of the inheritance of pectus
414 excavatum. *J Pediatr Surg* 2006; 41:1699–1703.
- 415 3. Kelly RE, Shamberger RC, Mellins RB, et al. Prospective multicenter study of surgical
416 correction of pectus excavatum: design, perioperative complications, pain, and baseline
417 pulmonary function facilitated by internet-based data collection. *J Am Coll Surg* 2007;
418 205:205–216.
- 419 4. Dietz HC, Cutting CR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo
420 missense mutation in the fibrillin gene. *Nature* 1991; 352: 337–339.
- 421 5. Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical
422 outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1
423 mutations: an international study. *Am J Hum Genet* 2007; 81: 454–466.
- 424 6. Judge DP, Biery NJ, Dietz HC. Characterization of microsatellite markers flanking FBN1:
425 utility in the diagnostic evaluation for Marfan syndrome. *Am J Med Genet* 2001; 99: 39–47.
- 426 7. Gurnett CA, Alaei F, Bowcock A, et al. Genetic linkage localizes an adolescent idiopathic
427 scoliosis and pectus excavatum gene to chromosome 18 q. *Spine* 2009; 34: E94–E100.

- 428 8. Carter, CO. Inheritance of congenital pyloric stenosis. British Medical Bulletin 1961; 117:
429 251-253.
- 430 9. Kantarci, OH, Barcellos LF, Atkinson EJ, Ramsay PP, De Andrade M, Hauser SL,
431 Weinschenker BG. Men transmit MS more often to their children vs women: the Carter effect.
432 Neurology 2006; 67: 305-310.
- 433 10. Kruse LM, Dobbs MB, Gurnett, CA. Polygenic threshold model with sex dimorphism in
434 clubfoot inheritance: the Carter effect. J Bone Joint Surg Am 2008; 90:268-2694.
- 435 11. Graph Pad Software [Chi Square Calculator]. La Jolla, CA: Graph Pad Software, Inc, 2005.
- 436 12. McDonald JH. Handbook of Biological Statistics. Baltimore: Sparky House Publishing,
437 2008: 21–28.
- 438 13. NCBI: National Center for Biotechnology Information [Human Genome Resources].
439 Available at: <http://www.ncbi.nlm.nih.gov/projects/genome/guide/human> Accessed March 2,
440 2010.
- 441 14. “How Tall/Thin are you PE people??” Pectus Support Group, 2004. Available at:
442 www.pectusinfo.com/board/stats.php Accessed December 1, 2008.
- 443 15. Crow JF. The origins, patterns and implications of human spontaneous mutation. Nat Rev
444 Genet 2000; 1:40–47.
- 445 16. McDowell MA, Fryar CD, Ogden CL, Flegal KM. (2008) Anthropometric reference data for
446 children and adults: United States, 2003-2006. National Health Statistics Report 10. US Dept
447 of Health and Human Services, Center for Disease Control and Prevention, National Center
448 for Health Statistics, 2008:1–48.

- 449 17. Lefebvre V, Li P, de Crombrughe, B. A new long form of Sox5 (L-Sox5), Sox6 and Sox9
450 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene.
451 *Embo J* 1998; 17:5718–5733.
- 452 18. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by
453 maternal heterodisomy in nondeletion Prader-Willi syndrome. *Nature* 1998; 342:281–285.
- 454 19. Walter CA, Intano GW, McCarrey JR, McMahan CA. Mutation frequency declines during
455 spermatogenesis in young mice but increases in old mice. *Proc Natl Acad Sci USA* 1998;
456 95:10015–10019.
- 457 20. Risch N, Reigh EW, Wishnick MW, McCarthy JG. Spontaneous mutation and parental age
458 in humans. A detailed review and analysis of the classical literature on the paternal age
459 effect. *Am J Hum Genet* 1987; 41:218–248.
- 460 21. Dean JCS. Marfan syndrome: clinical diagnosis and management. *Euro Jour Hum Genet*
461 2007; 15:724–733.
- 462 22. Frydman M. The Marfan Syndrome. *Isr Med Assoc J* 2008; 10:175–178.
- 463 23. Judge DP, Dietz HC. Marfan’s Syndrome. *Lancet* 2005; 366:1965–1976.
- 464 24. DePaepe A, Dietz HC, Devereux RB, Hennekem R, Pyeritz RE. Revised diagnostic criteria
465 for the Marfan syndrome. *Am J Med Genet* 1996; 62:417–426.
- 466 25. Lopez VM, Perez AB, Moisés VA, et al. Serial clinical and echocardiographic evaluation in
467 children with Marfan syndrome. *Arq Bras Cardiol* 2005; 85:314–318.
- 468 26. De Backer JF, Devos D, Segers P, et al. Primary impairment of left ventricular function in
469 Marfan syndrome. *Int J Cardiol* 2006; 112:353–358.
- 470 27. Taub CC, Stoler JM, Perez-Sanz T, et al. Mitral valve prolapse in Marfan syndrome: an old
471 topic revisited. *Echocardiography* 2009; 26: 357–364.

- 472 28. Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the
473 microfibrillar-fiber system in the Marfan syndrome. *N Engl J Med* 1990; 323:152–159.
- 474 29. Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L. Location on chromosome
475 15 of the gene defect causing Marfan syndrome. *N Engl J Med* 1990; 323:935–939.
- 476 30. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in
477 Marfan syndrome. *Nat Genet* 2004; 36:855–860.
- 478 31. Doege KJ, Coulter SN, Meek LM, Maslen K, Wood JG. A human-specific polymorphism in
479 the coding region of the aggrecan gene. Variable number of tandem repeats produce a range
480 of core protein sizes in the general population. *J Biol Chem* 1997; 272:13974–13979.
- 481 32. Skandalis SS, Theocharis AD, Vynios DH, et al. Cartilage aggrecan undergoes significant
482 compositional and structural alterations during laryngeal cancer. *Biochim Biophys Acta*
483 2006;1760:1046–1053.
- 484 33. Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the
485 Marfan-like disorder, congenital contractural arachnodactyly. *Nat Genet* 1995;11:456–458.
- 486 34. Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and
487 functional studies in asthma and immune-mediated diseases. *Curr Opin Allergy Clin*
488 *Immunol* 2009;9:401–408.
- 489 35. Randolph AG, Lange C, Silverman EK, et al. The IL12B gene is associated with asthma. *Am*
490 *J Hum Genet* 2004;75:709–715.
- 491 36. Castro-Giner F, de Cid R, Gonzalez JR, et al. Positionally cloned genes and age-specific
492 effects in asthma and atopy: an international population-based cohort study (ECRHS).
493 *Thorax* 2010;65:124–131.

- 494 37. Wu H, Romieu I, Sienna-Monge JJ, Li H, del Rio-Navarro BE, London SJ. Genetic variation
495 in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and childhood asthma. *Allergy*
496 2009;64:629–635.
- 497 38. Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. *Curr Opin Genet Dev*
498 2009;19:279–282.
- 499 39. Pazár B, Gergely P, Nagy ZB, et al. Role of HLA-DRB1 and PTPN22 genes in susceptibility
500 to juvenile idiopathic arthritis in Hungarian patients. *Clin Exp Rheumatol* 2008;26:1146–
501 1152.
- 502 40. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid
503 arthritis-implications for pathogenesis. *Nat Rev Rheumatol* 2010;6:290-295.
- 504 41. Hinks A, Eyre S, Ke X, et al. Association of the AFF3 gene and IL2/IL21 gene region with
505 juvenile idiopathic arthritis. *Genes Immun* 2010;11:194–198.
- 506 42. Hinks A, Eyre S, Ke X, et al. Overlap of disease susceptibility loci for rheumatoid arthritis
507 (RA) and juvenile idiopathic arthritis (JIA). *Ann Rheum Dis* 2009; doi: 10.1136/ard.2009.
508 110650.
- 509 43. Albers HM, Kurreeman FA, Stoeken-Rijsbergen G, et al. Association of the autoimmunity
510 locus 4q27 with juvenile idiopathic arthritis. *Arthritis Rheum* 2009;60:901–904.
- 511 44. Yao TC, Tsai YC, Huang JL. Association of RANTES promoter polymorphism with juvenile
512 rheumatoid arthritis. *Arthritis Rheum* 2009;60:1173–1178.
- 513 45. Rommelse NNJ, Arias-Vasquez A, Altink ME, et al. Neuropsychological endophenotype
514 approach to genome-wide linkage analysis identifies susceptibility loci for ADHD on 2q21.1
515 and 13q12.11. *Am J Hum Genet* 2008;83:294.

- 516 46. Banaschewski T, Becker K, Scherag S, Franke B, Coghill D. Molecular genetics of attention-
517 deficit/hyperactivity disorder: an overview. *Eur Child Adolesc Psychiatry* 2010;19:237–257.
- 518 47. Ogdie MN, Fisher SE, Yang M, et al. Attention deficit hyperactivity disorder: fine mapping
519 supports linkage to 5p13, 6q12, 16p13, and 17p11. *Am J Hum Genet* 2004;75:661–668.
- 520 48. Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI
521 response in depression may be influenced by SNPs in HTR1B and HTR1A. *Psychiatr Genet*
522 2009;19:281–291.
- 523 49. Viikki M, Kampman O, Illi A, et al. TPH1 218A/C polymorphism is associated with major
524 depressive disorder and its treatment response. *Neurosci Lett* 2010;468:80–84.
- 525 50. Lavebratt C, Aberg E, Sjöholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are
526 suggestively associated with depression in a Swedish population-based cohort. *J Affect*
527 *Disord* 2010; doi:10.1016/j.jad.2010.02.113.
- 528 51. Utge S, Soronen P, Partonen T, et al. A population-based association study of candidate
529 genes for depression and sleep disturbance. *Am J Med Genet B Neuropsychiatr Genet*
530 2010;153B:468–476.
- 531 52. Frodl T, Reinhold E, Koutsouleris N, et al. Childhood Stress, Serotonin Transporter Gene
532 and Brain Structures in Major Depression. *Neuropsychopharmacology* 2010;35:1383–1390.
- 533 53. Rivera M, Gutiérrez B, Molina E, et al. High-activity variants of the MAOA polymorphism
534 increase the risk for depression in a large primary care sample. *Am J Med Genet B*
535 *Neuropsychiatr Genet* 2009;150B:395–402.
- 536 54. Lucotte G, Mercier G, Diéterlen F, Yuasa I. A decreasing gradient of 374F allele frequencies
537 in the skin pigmentation gene SLC45A2, from the north of West Europe to North Africa.
538 *Biochem Genet* 2010;48:26–33.

- 539 55. Sturm RA. Molecular genetics of human pigmentation diversity. *Hum Mol Genet*
540 2009;18:R9–R17.
- 541 56. Bouakaze C, Keyser C, Crubézy E, Montagnon D, Ludes B. Pigment phenotype and
542 biogeographical ancestry from ancient skeletal remains: inferences from multiplexed
543 autosomal SNP analysis. *Int J Legal Med* 2009;123:315–325.
- 544 57. Latreille J, Ezzedine K, Elfakir A, et al. MC1R gene polymorphism affects skin color and
545 phenotypic features related to sun sensitivity in a population of French adult women.
546 *Photochem Photobiol* 2009;85:1451–1458.
- 547 58. Hildebrand MS, Tack D, McMordie SJ, et al. Audioprofile-directed screening identifies
548 novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. *Genet Med*
549 2008;10:797–804.
- 550 59. Rodríguez-Ballesteros M, Reynoso R, Olarte M, et al. A multicenter study on the prevalence
551 and spectrum of mutations in the otoferlin gene (OTOF) in subjects with nonsyndromic
552 hearing impairment and auditory neuropathy. *Hum Mutat* 2008;29:823–831.
- 553 60. Bartsch O, Vatter A, Zechner U, et al. GJB2 Mutations and Genotype-Phenotype Correlation
554 in 335 Patients from Germany with Nonsyndromic Sensorineural Hearing Loss: Evidence for
555 Additional Recessive Mutations Not Detected by Current Methods. *Audiol Neurootol*
556 2010;15:375–382.
- 557 61. Zadro C, Alemanno MS, Bellacchio E, et al. Are MYO1C and MYO1F associated with
558 hearing loss? *Biochim Biophys Acta* 2009;1792:27–32.
- 559 62. Sulem P, Gudbjartsson DF, Stacey SN, et al. Two newly identified genetic determinants of
560 pigmentation in Europeans. *Nat Genet* 2008;40:835–837.

- 561 63. Sturm RA, Larsson M. Genetics of human iris colour and patterns. *Pigment Cell Melanoma*
562 *Res* 2009;22:544–562.
- 563 64. Sturm RA, Duffy DL, Zhao ZZ, et al. A single SNP in an evolutionary conserved region
564 within intron 86 of the *HERC2* gene determines human blue-brown eye color. *Am J Hum*
565 *Genet* 2008;82:424–431.
- 566 65. Shekar SN, Duffy DL, Frudakis T, et al. Linkage and association analysis of
567 spectrophotometrically quantified hair color in Australian adolescents: the effect of *OCA2*
568 and *HERC2*. *J Invest Dermatol* 2008;128:2807–2814.
- 569 66. Tully G. Genotype versus phenotype: human pigmentation. *Forensic Sci Int Genet*
570 2007;1:105–110.
- 571 67. Lea RA, Shepherd AG, Curtain RP, et al. A typical migraine susceptibility region localizes to
572 chromosome 1q31. *Neurogenetics* 2002;4:17–22.
- 573 68. Bjornsson A, Gudmundsson G, Gudfinnsson E, et al. Localization of a gene for migraine
574 without aura to chromosome 4q21. *Am J Hum Genet* 2005;76: 715.
- 575 69. Nyholt DR, Morley KI, Ferreira MAR, et al. Genomewide significant linkage to migrainous
576 headache on chromosome 5q21. *Am J Hum Genet* 2005;77:500–512.
- 577 70. Carlsson A, Forsgren L, Nylander PO, et al. Identification of a susceptibility locus for
578 migraine with and without aura on 6p12.2-p21.1. *Neurology* 2002;59:1804–1807.
- 579 71. Russo L, Mariotti P, Sangiorgi E, et al. A new susceptibility locus for migraine with aura in
580 the 15q11-q13 genomic region containing three GABA-A receptor genes. *Am J Hum Genet*
581 2005;76:327–333.

- 582 72. Nyholt DR, Lea RA, Goadsby PJ, Brimage PJ, Griffiths LR. Familial typical migraine:
583 linkage to chromosome 19p13 and evidence for genetic heterogeneity. *Neurology*
584 1998;50:1428–1432.
- 585 73. Lea RA, Hilton DA, MacMillian JC, Griffiths LR. An analysis of clinical characteristics in
586 genetically linked migraine-affected pedigrees. *Cephalalgia* 2003;23:808–813.
- 587 74. Nyholt DR, Curtain RP, Griffiths LR. Familial typical migraine: significant linkage and
588 localization of a gene to Xq24-28. *Hum Genet* 2000;107:18–23.
- 589 75. Szombathy T, Jánoskúti L, Szalai C, et al. Angiotensin II type 1 receptor gene polymorphism
590 and mitral valve prolapse syndrome. *Am Heart J* 2000;139:101–105.
- 591 76. Freed LA, Acierno JS, Dai D, et al. A locus for autosomal dominant mitral valve prolapse on
592 chromosome 11p15.4. *Am J Hum Genet* 2003;72:1551–1559.
- 593 77. Nesta F, Leyne M, Yosefy C, et al. New locus for autosomal dominant mitral valve prolapse
594 on chromosome 13: clinical insights from genetic studies. *Circulation* 2005;112:2022–2030.
- 595 78. Diss S, Abergel E, Berrebi A, et al. Mapping of a first locus for autosomal dominant
596 myxomatous mitral-valve prolapse to chromosome 16p11.2-p12.1. *Am J Hum Genet*
597 1999;65:1242–1251.
- 598 79. Wojciechowski R, Moy C, Ciner E, et al. Genomewide scan in Ashkenazi Jewish families
599 demonstrates evidence of linkage of ocular refraction to a QTL on chromosome 1p36. *Hum*
600 *Genet* 2006;119:389–399.
- 601 80. Chen CY, Stankovich J, Scurrah KJ, et al. Linkage replication of the MYP12 locus in
602 common myopia. *Invest Ophthalmol Vis Sci* 2007;48:4433–4439.

- 603 81. Hammond CJ, Andrew T, Mak YT, Spector TD. A susceptibility locus for myopia in the
604 normal population is linked to the PAX6 gene region on chromosome 11: a genomewide scan
605 of dizygotic twins. *Am J Hum Genet* 2004;75:294–304.
- 606 82. Zhang, Q, Guo, X, Xiao, X, Jia, X, Li, S, Hejtmancik, JF. A new locus for autosomal
607 dominant high myopia maps to 4q22-q27 between D4S1578 and D4S1612. *Molec Vis*
608 2005;11:554–560.
- 609 83. Lam CY, Tam POS, Fan DSP, et al. A genome-wide scan maps a novel high myopia locus to
610 5p15. *Invest Ophthal Vis Sci* 2008;49:3768–2778.
- 611 84. Naiglin L, Gazagne C, Dallongeville F, et al. A genome wide scan for familial high myopia
612 suggests a novel locus on chromosome 7q36. *J Med Genet* 2002;39:118–124.
- 613 85. Paget S, Julia S, Vitezica ZG, Soler V, Malecaze F, Calvas P. Linkage analysis of high
614 myopia susceptibility locus in 26 families. *Molec Vis* 2008;14:2566–2574.
- 615 86. Young TL, Ronan SM, Alvear AB, et al. A second locus for familial myopia maps to
616 chromosome 12q. *Am J Hum Genet* 1998;63:1419–1424.
- 617 87. Paluru P, Ronan SM, Heon E, et al. New locus for autosomal dominant high myopia maps to
618 the long arm of chromosome 17. *Invest Ophthal Vis Sci* 2003;44:1830–1836.
- 619 88. Bartsocas CS, Kastrantas AD. X-linked form of myopia. *Hum Hered* 1981;31:199–200.
- 620 89. Zhang Q, Li S, Xiao X, Jia X, Guo X. Confirmation of a genetic locus for X-linked recessive
621 high myopia outside MYP1. *J Med Genet* 2007;52:469–472.
- 622 90. Bergren SK, Chen S, Galecki A, Kearney JA. Genetic modifiers affecting severity of
623 epilepsy caused by mutation of sodium channel Scn2a. *Mamm Genome* 2005;16:683–690.
- 624 91. Erez A, Patel AJ, Wang X, et al. Alu-specific microhomology-mediated deletions in CDKL5
625 in females with early-onset seizure disorder. *Neurogenetics* 2009;10:363–369.

- 626 92. Gao X, Gordon D, Zhang D, et al. CHD7 gene polymorphisms are associated with
627 susceptibility to idiopathic scoliosis. *Am J Hum Genet* 2007;80:957–965.
- 628 93. Ocaka L, Zhao C, Reed JA, et al. Assignment of two loci for autosomal dominant adolescent
629 idiopathic scoliosis to chromosomes 9q31.2-q34.2 and 17q25.3-qtel. *J Med Genet*
630 2008;45:87–92.
- 631 94. Salehi LB, Mangino M, De Serio S, et al. Assignment of a locus for autosomal dominant
632 idiopathic scoliosis (IS) to human chromosome 17p11. *Hum Genet* 111:401–404.
- 633 95. Chan V, Fong GCY, Luk KDK, et al. A genetic locus for adolescent idiopathic scoliosis
634 linked to chromosome 19p13.3. *Am J Hum Genet* 2002;71:401–406.
- 635 96. Sanna S, Jackson AU, Nagaraja R, et al. Common variants in the GDF5-UQCC region are
636 associated with variation in human height. *Nat Genet* 2008;40:198–203.
- 637 97. Tunçbilek E, Alanay Y. Congenital contractural arachnodactyly (Beals syndrome). *Orphanet*
638 *J Rare Dis* 2006;1:20.
- 639 98. Callewaert BL, Loeys BL, Ficcadenti A, et al. Comprehensive clinical and molecular
640 assessment of 32 probands with congenital contractural arachnodactyly: report of 14 novel
641 mutations and review of the literature. *Hum Mutat* 2009;30:334–341.
- 642 99. Gao LG, Luo F, Hui RT, Zhou XL. Recent molecular biological progress in Marfan
643 syndrome and Marfan-associated disorders. *Ageing Res Rev* 2009; doi:10.1016/j.arr.2009.
644 09.001.
- 645 100. Mamada M, Yorifuji T, Yorifuji J, et al. Fibrillin I gene polymorphism is associated with
646 tall stature of normal individuals. *Hum Genet* 2007;120:733–735.

647 **Figure Legends**

648

649

650 **Figure 1. Pedigree with traits added for the mother, father and proband (additional family**
651 **member traits not included here for clarity).** Father and proband have pectus excavatum
652 (darkened symbol). Proband is labeled with an arrow.

653

654 **Figure 2. Genomic map of chromosomal gene locations for traits evaluated in this study of**
655 **pectus excavatum** The genes for asthma include CHI3L1 (1q32.1) (34), IL12B (5q31.1-q33.1)
656 (35), NPSR1 (7p14.3) (36), ORMDL3 (17q12-q21.1) (37), and ADAM33 (20p13) (38). The
657 genes used for arthritis include PTPN22 (1p13.3-p13.1) (39), FCRL3 (1q21-q22) (40), AFF3
658 (2q11.2-q12) (41), STAT4 (2q32.2-q32.3) (42), IL2 (4q26- q27) (43), HLA-DRB1 (6p21.3) (40),
659 TRAF1 (9q33-q34) (42), and CCL5 (17q11.2-q12) (44). The genes used for ADHD include
660 ADHD5 (2q21.1) (45), DRD5 (4p16.1) (46), SLC6A3 (5p15.3) (46), ADHD4 (5p13)
661 (47), ADHD3 (6q12) (47), HTR1B (6q13) (46), DRD4 (11p15.5) (46), TPH2 (12q21.1) (46),
662 ADHD6 (13q12.11) (45), ADHD1 (16p13) (47), ADHD2 (17p11) (47), and SNAP-25 (20p12-
663 p11.2) (46). The genes used for depression include HTR1A (5q11.2-q13) (48), TPH1 (11p15.3-
664 p14) (49), BDNF (11p13) (50), TPH2 (12q21.1) (51), SLC6A4 (17q11.1-q12) (52), and MAOA
665 (Xp11.3) (53). The genes used for fair skin include SLC45A2 (5p13.2) (54), SLC24A5 (15q21.1)
666 (55), HERC2 (15q13) (56), and MC1R (16q24.3) (57). The genes used for hearing loss include
667 KCNQ4 (1p34) (58), OTOF (2p23.1) (59), GJB2 (13q11-q12) (60), MYO1C (17p13) (61), and
668 MYO1F (19p13.3-p13.2) (61). The genes used for light eyes include SLC45A2 (5p13.2) (56),
669 SHEP11 (9p23) (62), OCA2 (15q11.2-12) (63), and HERC2 (15q13) (64). The genes used for
670 light hair include SHEP11 (9p23) (62), OCA2 (15q11.2-12) (65), HERC2 (15q13) (65), MC1R
671 (16q24.3) (57), and ASIP (20q11.2-q12) (66). The genes used for migraines include MGR

672 (1q31) (67), MA (4q24) (68), MGR8 (5q21) (69), MGR3 (6p21.1-12.2) (70), MGR7 (15q11.2-
673 q12) (71), MGR5 (19p13) (72), CACNA1A (19p13.2-13.1) (73), and MGR2 (Xq24-q28) (74).
674 The genes used for mitral valve prolapse include AGTR1 (3q21-25) (75), MMVP2 (11p15.4)
675 (76), MMVP3 (13q31.3-q32.1) (77), and MMVP1 (16p12.1-p11.2) (78). The genes used for
676 myopia include MYP14 (1p36) (79), MYP12 (2q37.1) (80), MYP8 (3q26) (81), MYP11 (4q22-
677 q27) (82), MYP9 (4q12) (78), MYP16 (5p15.33-p15.2) (83), MYP4 (7q36) (84), MYP17 (7p15)
678 (85), MYP10 (8p23) (81), MYP7 (11p13) (81), MYP3 (12q21-q23) (86), MYP5 (17q21-q22)
679 (87), MYP1 (Xq28) (88), and MYP13 (Xq23-q25) (89). The genes used for seizures include
680 SCN2A (2q23-24) (90) and CDKL5 (Xp22) (91). The genes used for scoliosis include CHD7
681 (8q12.1-12.2) (92), IS4 (9q31.2-q34.2) (93), IS2 (17p11.2) (94), IS5 (17q25.3) (93), and AIS
682 (19p13.3) (95). The gene used for tallness is GDF5 (20q11.2) (96). The gene used for Congenital
683 Contractural Arachnodactyly (CCA, or Beals-Hecht syndrome), which can include symptoms
684 such as long fingers, tall, thin, scoliosis, and mitral valve prolapse (97-99), is FBN2 (5q23-q31)
685 (33). The gene used for Marfan Syndrome, which can include symptoms such as tall, thin, long
686 fingers, scoliosis, and mitral valve prolapse (8, 99, 100), is FBN1 (15q21.1) (7).

687

688 **Figure 3. Traits present in parents and/or proband.** Traits assayed here include the 10 traits
689 we find most frequently associated with pectus excavatum. Traits shared between the proband
690 and both parents are represented by yellow cells, between the proband and the mother by pink
691 cells, between the proband and father, by light blue cells, in the proband only, by gray cells, in
692 the mother only by dark red cells, in the father only by black cells, and between the mother and
693 father by green cells.

694

695

Table 1

696 The ten clinical traits found to be most frequently associated with pectus excavatum (PE), ranked

697 by prevalence, for individuals with PE and their relatives

698

699

700

701

702

703

704

705

706

707

Trait	PE		Non-PE	
	%	Rank	%	Rank
Thinness	47.41	1	3.55	7
Braces	41.38	2	5.17	5
Myopia	39.66	3	10.93	1
Tallness	32.76	4	7.13	2
Light Eyes	29.31	5	7.09	3
Long Fingers	25.00	6	1.72	19
Creativity	25.00	7	3.35	8
Crowded Teeth	25.00	8	2.46	13
Fair Skin	21.55	9	5.81	4
Asthma	19.83	10	1.67	21
Light Hair	14.66	13	3.10	9
Arthritis	12.07	16	4.92	6
Depression	8.63	22	3.00	10

708

709

Table 2

710 Transmission of pectus excavatum (PE) from affected fathers versus affected mothers to their

711 children.

Individuals	# children in sibship with PE	# children in sibship without PE	Chi-square P value	Odds Ratio (female: male)	95% Confidence Interval for Odds Ratio
Affected fathers (for all children)	20	39	0.008	3.900	1.42-10.65
Affected mothers	16	8			

712

713

714

715

Affected fathers	4	19
------------------	---	----

	Affected fathers (for female children)	4	19			716
717	Affected mothers	7	3	0.006	11.083	1.966-
	Affected fathers (for male children)	16	20			
	Affected mothers	9	5	0.245	2.137	0.595- 7.685

718
719
720

Table 3

721 Differential prevalence of pectus excavatum in siblings of affected mothers versus affected
722 fathers.

Individuals	# siblings with PE	# siblings without PE	Chi-square P value	Odds Ratio (female: male)	95% Confidence Interval for Odds Ratio
Affected Fathers	7	89			
Affected Mothers	9	18	0.001	6.357	2.095- 19.291

723